SG10201608684QA - Injectable formulation - Google Patents

First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=49483139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201608684Q(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-23Application filed by Otsuka Pharma Co LtdfiledCriticalOtsuka Pharma Co Ltd

2016-12-29Publication of SG10201608684QApublicationCriticalpatent/SG10201608684QA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Dispersion Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10201608684QA2012-04-232013-04-23Injectable formulationSG10201608684QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261636932P	2012-04-23	2012-04-23
US201361791896P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
SG10201608684QAtrue SG10201608684QA (en)	2016-12-29

Family

ID=49483139

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201608684QASG10201608684QA (en)	2012-04-23	2013-04-23	Injectable formulation
SG11201406775UASG11201406775UA (en)	2012-04-23	2013-04-23	Injectable formulation

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201406775UASG11201406775UA (en)	2012-04-23	2013-04-23	Injectable formulation

Country Status (31)

Country	Link
US (6)	US20150086632A1 (en)
EP (1)	EP2868318B2 (en)
JP (1)	JP6249944B2 (en)
KR (1)	KR102168263B1 (en)
CN (4)	CN110638752A (en)
AR (1)	AR090775A1 (en)
AU (1)	AU2013253518B2 (en)
BR (1)	BR112014026398B1 (en)
CA (1)	CA2871398C (en)
CO (1)	CO7151499A2 (en)
CY (1)	CY1123195T1 (en)
DK (1)	DK2868318T4 (en)
EA (1)	EA026124B1 (en)
ES (1)	ES2727454T5 (en)
HR (1)	HRP20190841T4 (en)
HU (1)	HUE043686T2 (en)
IL (1)	IL235211A0 (en)
IN (1)	IN2014DN08870A (en)
JO (1)	JO3524B1 (en)
LT (1)	LT2868318T (en)
MX (1)	MX361722B (en)
MY (1)	MY169099A (en)
NZ (1)	NZ630255A (en)
PH (1)	PH12014502366A1 (en)
PL (1)	PL2868318T5 (en)
PT (1)	PT2868318T (en)
SG (2)	SG10201608684QA (en)
SI (1)	SI2868318T2 (en)
TW (1)	TWI641395B (en)
UA (1)	UA118084C2 (en)
WO (1)	WO2013161830A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20200109A1 (en)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	Injectable preparation
TWI562991B (en)	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20210047A1 (en)*	2012-10-25	2017-06-16	Otsuka Pharma Co Ltd	Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
WO2017106641A1 (en)*	2015-12-17	2017-06-22	Assia Chemical Industries Ltd.	Solid state forms of brexpiprazole
WO2017134038A1 (en)*	2016-02-01	2017-08-10	Hexal Ag	Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en)*	2016-05-31	2017-12-07	Cipla Limited	A new stable polymorph of brexpiprazole and process for preparation thereof
WO2018033483A1 (en)*	2016-08-16	2018-02-22	H E X A L Aktiengesellschaft	Pharmaceutical compositions of a benzothiophene compound
EP3577111A1 (en)*	2017-02-02	2019-12-11	Hexal Aktiengesellschaft	Crystalline brexpiprazole
CN113645954B (en)*	2019-03-28	2024-03-29	大塚制药株式会社	Lyophilized compositions containing benzazepine compounds
JPWO2021029020A1 (en)*	2019-08-13	2021-02-18
EP4400097A4 (en)*	2021-09-07	2025-06-25	Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.	Long-acting brexpiprazole preparation for injection and preparation method therefor
CN117214053A (en)*	2023-10-17	2023-12-12	海南卫康制药(潜山)有限公司	Particle size determination method of cefuroxime sodium intramuscular injection suspension for injection

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2284202T3 (en)	1997-05-14	2007-11-01	Senju Pharmaceutical Co., Ltd.	WATERPROOF PREPARATIONS IN SUSPENSION WITH EXCELLENT REDISPERSABILITY.
JP3402195B2 (en)*	1997-05-14	2003-04-28	千寿製薬株式会社	Aqueous suspension with good redispersibility
US6656505B2 (en)*	2000-07-21	2003-12-02	Alpharma Uspd Inc.	Method for forming an aqueous flocculated suspension
US20030195179A1 (en)	2000-08-25	2003-10-16	Shirou Sawa	Aqueous suspension preparations
AR033485A1 (en)*	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME
US20050032811A1 (en)*	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
WO2005041937A2 (en)*	2003-10-23	2005-05-12	Otsuka Pharmaceutical Co., Ltd.	Controlled release sterile injectable aripiprazole formulation and method
JP4315393B2 (en)	2005-04-14	2009-08-19	大塚製薬株式会社	Heterocyclic compounds
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
EP1933814A2 (en)*	2005-09-15	2008-06-25	Elan Pharma International Limited	Nanoparticulate aripiprazole formulations
TW200808375A (en)	2006-05-12	2008-02-16	Otsuka Pharma Co Ltd	Hydrogel suspension and manufacturing process thereof
TWI415629B (en)	2006-10-26	2013-11-21	Otsuka Pharma Co Ltd	Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
HUE036214T2 (en)	2007-07-31	2018-06-28	Otsuka Pharma Co Ltd	Methods of preparing an aripiprazole suspension and freeze-dried preparation
DK2262506T3 (en)*	2008-03-11	2014-06-10	Alcon Res Ltd	HIGHLY FLOCCULATED TRIAMCINOLONACETONIDE SUSPENSIONS WITH LOW VISCOSITY FOR INTRAVITREAL INJECTION
JP5685193B2 (en)*	2008-11-19	2015-03-18	メリアルリミテッド	Formulation containing ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
RU2535089C2 (en)*	2010-08-24	2014-12-10	Оцука Фармасьютикал Ко., Лтд.	Suspension and hardened composition containing carbostyril derivative and silicone oil and/or silicone oil derivative
CN107625728A (en)*	2010-10-18	2018-01-26	大日本住友制药株式会社	Injectable sustained release preparation
RS55434B1 (en)*	2011-03-18	2017-04-28	Alkermes Pharma Ireland Ltd	Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
JP2012232958A (en)	2011-05-09	2012-11-29	Otsuka Pharmaceut Co Ltd	Injection preparation
WO2013142205A1 (en)*	2012-03-19	2013-09-26	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising benzyl alcohol
TWI562991B (en)†	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (en)*	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	Injectable preparation

2013
- 2013-04-22ARARP130101320Apatent/AR090775A1/ennot_activeApplication Discontinuation
- 2013-04-23CNCN201911077087.1Apatent/CN110638752A/enactivePending
- 2013-04-23USUS14/395,681patent/US20150086632A1/ennot_activeAbandoned
- 2013-04-23ININ8870DEN2014patent/IN2014DN08870A/enunknown
- 2013-04-23PTPT13781458Tpatent/PT2868318T/enunknown
- 2013-04-23WOPCT/JP2013/061950patent/WO2013161830A1/enactiveApplication Filing
- 2013-04-23HUHUE13781458Apatent/HUE043686T2/enunknown
- 2013-04-23BRBR112014026398-1Apatent/BR112014026398B1/enactiveIP Right Grant
- 2013-04-23DKDK13781458.8Tpatent/DK2868318T4/enactive
- 2013-04-23NZNZ630255Apatent/NZ630255A/enunknown
- 2013-04-23SISI201331442Tpatent/SI2868318T2/enunknown
- 2013-04-23PLPL13781458Tpatent/PL2868318T5/enunknown
- 2013-04-23CNCN201710701596.1Apatent/CN107536802A/enactivePending
- 2013-04-23TWTW102114433Apatent/TWI641395B/enactive
- 2013-04-23EPEP13781458.8Apatent/EP2868318B2/enactiveActive
- 2013-04-23LTLTEP13781458.8Tpatent/LT2868318T/enunknown
- 2013-04-23HRHRP20190841TTpatent/HRP20190841T4/enunknown
- 2013-04-23JPJP2014512621Apatent/JP6249944B2/enactiveActive
- 2013-04-23ESES13781458Tpatent/ES2727454T5/enactiveActive
- 2013-04-23SGSG10201608684QApatent/SG10201608684QA/enunknown
- 2013-04-23CACA2871398Apatent/CA2871398C/enactiveActive
- 2013-04-23CNCN202010921162.4Apatent/CN111888329A/enactivePending
- 2013-04-23EAEA201491937Apatent/EA026124B1/ennot_activeIP Right Cessation
- 2013-04-23KRKR1020147032097Apatent/KR102168263B1/enactiveActive
- 2013-04-23CNCN201380021612.2Apatent/CN104363912A/enactivePending
- 2013-04-23MYMYPI2014703102Apatent/MY169099A/enunknown
- 2013-04-23UAUAA201412554Apatent/UA118084C2/enunknown
- 2013-04-23JOJOP/2013/0115Apatent/JO3524B1/enactive
- 2013-04-23AUAU2013253518Apatent/AU2013253518B2/enactiveActive
- 2013-04-23MXMX2014012734Apatent/MX361722B/enactiveIP Right Grant
- 2013-04-23SGSG11201406775UApatent/SG11201406775UA/enunknown
2014
- 2014-10-20ILIL235211Apatent/IL235211A0/enactiveIP Right Grant
- 2014-10-22PHPH12014502366Apatent/PH12014502366A1/enunknown
- 2014-11-21COCO14255947Apatent/CO7151499A2/enunknown
2017
- 2017-09-12USUS15/702,361patent/US10624889B2/enactiveActive
2019
- 2019-06-06CYCY20191100602Tpatent/CY1123195T1/enunknown
2020
- 2020-01-28USUS16/775,222patent/US20200163960A1/ennot_activeAbandoned
2022
- 2022-02-11USUS17/650,822patent/US20220305007A1/ennot_activeAbandoned
2023
- 2023-12-15USUS18/541,083patent/US20240277702A1/ennot_activeAbandoned
2024
- 2024-11-22USUS18/956,268patent/US20250241909A1/enactivePending

Also Published As

Publication number	Publication date
CN104363912A (en)	2015-02-18
HRP20190841T1 (en)	2019-07-26
US20250241909A1 (en)	2025-07-31
PT2868318T (en)	2019-06-07
KR102168263B1 (en)	2020-10-21
EP2868318B2 (en)	2022-01-26
HRP20190841T4 (en)	2022-03-04
MX361722B (en)	2018-12-14
TWI641395B (en)	2018-11-21
US20180092910A1 (en)	2018-04-05
JP6249944B2 (en)	2017-12-20
EP2868318A1 (en)	2015-05-06
CY1123195T1 (en)	2021-10-29
CA2871398A1 (en)	2013-10-31
AU2013253518A1 (en)	2014-11-06
MX2014012734A (en)	2015-04-10
NZ630255A (en)	2016-05-27
DK2868318T3 (en)	2019-06-03
TW201406401A (en)	2014-02-16
PL2868318T3 (en)	2019-09-30
AU2013253518B2 (en)	2017-10-05
EP2868318A4 (en)	2015-12-09
CA2871398C (en)	2021-04-27
PH12014502366B1 (en)	2015-01-12
KR20150003336A (en)	2015-01-08
ES2727454T5 (en)	2022-05-13
LT2868318T (en)	2019-07-25
CN111888329A (en)	2020-11-06
DK2868318T4 (en)	2022-03-28
JPWO2013161830A1 (en)	2015-12-24
CN107536802A (en)	2018-01-05
US20220305007A1 (en)	2022-09-29
WO2013161830A1 (en)	2013-10-31
HK1205678A1 (en)	2015-12-24
US10624889B2 (en)	2020-04-21
AR090775A1 (en)	2014-12-03
EP2868318B1 (en)	2019-03-06
US20200163960A1 (en)	2020-05-28
SI2868318T2 (en)	2022-04-29
SI2868318T1 (en)	2019-06-28
MY169099A (en)	2019-02-18
SG11201406775UA (en)	2014-12-30
CO7151499A2 (en)	2014-12-29
IN2014DN08870A (en)	2015-05-22
PH12014502366A1 (en)	2015-01-12
BR112014026398A2 (en)	2017-06-27
US20150086632A1 (en)	2015-03-26
PL2868318T5 (en)	2022-06-20
EA201491937A1 (en)	2015-03-31
HUE043686T2 (en)	2019-09-30
US20240277702A1 (en)	2024-08-22
IL235211A0 (en)	2014-12-31
JO3524B1 (en)	2020-07-05
UA118084C2 (en)	2018-11-26
CN110638752A (en)	2020-01-03
ES2727454T3 (en)	2019-10-16
EA026124B1 (en)	2017-03-31
BR112014026398B1 (en)	2022-11-29

Publication	Publication Date	Title
IL235299A0 (en)	2014-12-31	Injectable preparation
IL235211A0 (en)	2014-12-31	Injectable formulation
IL235864A0 (en)	2015-02-01	Aprepitant injectable formulations
GB201217441D0 (en)	2012-11-14	Composition
GB201200707D0 (en)	2012-02-29	Composition
DK2825039T3 (en)	2017-11-27	Injectable ibuprofen formulation
ZA201306000B (en)	2014-04-30	Stable formulation
EP2878295A4 (en)	2015-12-23	Composition
EP2887953A4 (en)	2016-05-25	Improved daptomycin injectable formulation
GB201206035D0 (en)	2012-05-16	Composition
EP2910537A4 (en)	2016-06-29	Gas-generating-agent composition
GB201209597D0 (en)	2012-07-11	Composition
GB201208133D0 (en)	2012-06-20	Composition
GB201211247D0 (en)	2012-08-08	Improved formulation
GB201215753D0 (en)	2012-10-17	Composition
GB201215482D0 (en)	2012-10-17	Composition
GB201213425D0 (en)	2012-09-12	Composition
GB201213427D0 (en)	2012-09-12	Composition
GB201211938D0 (en)	2012-08-15	Composition
GB201211154D0 (en)	2012-08-08	Composition
GB201210301D0 (en)	2012-07-25	Composition
GB201209097D0 (en)	2012-07-04	Composition
GB201208992D0 (en)	2012-07-04	Composition
GB201205861D0 (en)	2012-05-16	Composition
GB201202695D0 (en)	2012-04-04	Composition

Movatterモバイル変換